Using a 24-hour continuous glucose monitor after delivery to predict future Type 2 diabetes risk in people with gestational diabetes
Postpartum Continuous Glucose Monitoring for Type 2 Diabetes Mellitus Risk Evaluation in Patients With Gestational Diabetes Mellitus: POSTPOD Trial
This pilot tests whether wearing a continuous glucose monitor for 24 hours immediately after delivery can help predict later Type 2 diabetes risk in people who had gestational diabetes.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | University of California, Los Angeles Academic / other |
| Locations | 1 site (Los Angeles, California) |
| Trial ID | NCT07449039 on ClinicalTrials.gov |
What this trial studies
This single-center pilot enrolls people with a confirmed gestational diabetes diagnosis who receive prenatal care and plan delivery at UCLA. Participants will have a continuous glucose monitor applied within two hours after delivery, wear it for 24 hours, and remove it themselves. Two brief surveys about the device experience and health will be completed at 1–3 months and again at 12–14 months postpartum. The study excludes people with pre-gestational diabetes, multifetal gestation, recent steroid or terbutaline use, certain medical conditions, or planned postpartum imaging, and it is designed to test feasibility and early predictive signal rather than provide diagnosis or treatment.
Who should consider this trial
Good fit: Ideal candidates are adults (≥18 years) with gestational diabetes who receive prenatal care and plan to deliver at UCLA Ronald Reagan or UCLA Santa Monica and who do not have pre-existing diabetes or other listed exclusions.
Not a fit: People with pre-gestational diabetes, multifetal pregnancies, certain infections or skin conditions at the sensor site, recent steroid/terbutaline or metformin use, or those not delivering at UCLA are not likely to benefit from this protocol.
Why it matters
Potential benefit: If successful, this approach could offer a simple, immediate way to identify people at higher risk of developing Type 2 diabetes so they can get earlier monitoring or prevention efforts.
How similar studies have performed: Continuous glucose monitoring has been used in pregnancy and postpartum settings to detect abnormal glucose patterns, but using immediate postpartum 24-hour CGM specifically to predict long-term Type 2 diabetes risk is a novel, early-stage approach with limited prior evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Prenatal care at UCLA Health * Planning to deliver at UCLA Ronald Reagan or UCLA Santa Monica * Confirmed gestational diabetes diagnosis based on 2-step approach * Maternal age \>= 18 years Exclusion Criteria: * Pre-gestational diabetes (T1DM or T2DM) * Multifetal gestation * Intra-amniotic infection by clinical criteria * Postpartum hemorrhage * Maternal ICU admission * Known allergy to medical-grade adhesive * Presence of skin lesions at anticipated CGM application site * Scheduled postpartum non-sonographic imaging study (radiograph, magnetic resonance imaging (MRI), or computed tomography (CT) scan) during trial * Metformin use * Steroid use * Terbutaline use within 4 hours of delivery * Cystic fibrosis * MODY (mature onset of diabetes in the young)
Where this trial is running
Los Angeles, California
- University of California, Los Angeles — Los Angeles, California, United States (Recruiting)
Study contacts
- Principal investigator: Christina Han, MD — University of California, Los Angeles
- Study coordinator: Rujuta Sathe
- Email: RSathe@mednet.ucla.edu
- Phone: 310-794-8893
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.